Incyte | Frais De Vente Et D'Administration



Selling And Administration Expenses Changement Date
Acadia Pharmaceuticals USD 130.08M 3.21M 2024-12
Agios Pharmaceuticals USD 51.7M 13.16M 2024-12
Alnylam Pharmaceuticals USD 295.34M 74.35M 2024-12
Amgen USD 1.88B 253M 2024-12
Biogen USD 677.3M 99.6M 2024-12
BioMarin Pharmaceutical USD 256.77M 46.81M 2024-12
Bristol-Myers Squibb USD 1.58B 521M 2025-03
Eli Lilly USD 2.36B 62.3M 2025-03
Exelixis USD 134.33M 22.53M 2025-01
Gilead Sciences USD 1.26B 603M 2025-03
Incyte USD 325.69M 1.02M 2025-03
Ionis Pharmaceuticals USD 76M 12.08M 2025-03
MacroGenics USD 27.81M 13.71M 2024-12
Merck USD 2.53B 319M 2025-03
Moderna USD 212M 139M 2025-03
Neurocrine Biosciences USD 287.8M 53.5M 2024-12
Novartis USD 3.5B 368M 2024-12
Novartis USD 3.5B 368M 2024-12
Pfizer USD 3.01B 1.27B 2025-03
PTC Therapeutics USD 84.68M 11.23M 2024-12
Regeneron Pharmaceuticals USD 633M 159.2M 2025-03
Sarepta Therapeutics USD 163.87M 35.67M 2024-12
Ultragenyx Pharmaceutical USD 82.49M 2.14M 2024-12
Vertex Pharmaceuticals USD 377.6M 5.8M 2024-12



Incyte Frais De Vente Et D'Administration - Les valeurs actuelles, des données historiques, des prévisions, des statistiques, des tableaux et le calendrier économique - May 2025.